RYR1
ENSG00000196218
Target class
Ion channel
Chromosome
19
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- RYR1
- Gene name
- Ryanodine receptor 1
- Gene symbol
- RYR1
- Protein name
- Ryanodine receptor 1 (RYR-1) (RyR1) (Skeletal muscle calcium release channel) (Skeletal muscle ryanodine receptor) (Skeletal muscle-type ryanodine receptor) (Type 1 ryanodine receptor)
- RYR
- PPP1R137
- MHS
- MHS1
- CCO
- Gene biotype
- Protein coding
- Gene family
- Ryanodine receptors|Protein phosphatase 1 regulatory subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 22
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 423.54
- Tissue specificity (Gini)
- 0.885
- Tissue specificity (tau)
- 0.994
- KEGG gene identifiers
- hsa:6261
- Protein interaction confidence
- 0.832
- Protein interaction partners
- 70
- R-HSA-2672351
- R-HSA-5578775
- End position
- 38595273
- Start position
- 38433691
- Chromosome
- 19
- Strand
- Forward
- Sarcoplasmic reticulum membrane
- Multi-pass membrane protein . Note=The number of predicted transmembrane domains varies between orthologs. Both N-terminus and C-terminus are cytoplasmic. .
- Cytosol
- Golgi apparatus
- Vesicles
Publication evidence
- PubMed 7556644
- Tissue specificity (tau)
- 0.993583
- Expression inequality (Gini)
- 0.885199
Expression in transcripts per million
- Muscle - Skeletal
- 423.54
- Brain - Cerebellum
- 21.28
- Brain - Cerebellar Hemisphere
- 15.42
- Brain - Hypothalamus
- 13.56
- Testis
- 8.7
Expression in transcripts per million
- Muscle - Skeletal423.54
- Brain - Cerebellum21.28
- Brain - Cerebellar Hemisphere15.42
- Brain - Hypothalamus13.56
- Testis8.7
- Brain - Cortex7.26
- Brain - Anterior cingulate cortex (BA24)6.13
- Brain - Frontal Cortex (BA9)5.93
- Brain - Amygdala5.19
- Brain - Nucleus accumbens (basal ganglia)5.12
- Brain - Caudate (basal ganglia)4.81
- Nerve - Tibial4.79
- Brain - Substantia nigra4.24
- Brain - Spinal cord (cervical c-1)4.09
- Brain - Hippocampus3.5
- Skin - Not Sun Exposed (Suprapubic)2.99
- Brain - Putamen (basal ganglia)2.85
- Skin - Sun Exposed (Lower leg)2.64
- Esophagus - Mucosa2.51
- Minor Salivary Gland1.58
- Vagina1.53
- Breast - Mammary Tissue1.01
- Colon - Sigmoid0.96
- Lung0.95
- Adipose - Visceral (Omentum)0.92
And 29 more, listed on the interactive page.
- GO:0001666
- GO:0006816
- GO:0006936
- GO:0051209
- GO:0070588
- GO:0071313
- GO:0005737
- GO:0005790
- GO:0005886
- GO:0005938
- GO:0014701
- GO:0031674
- GO:0033017
- GO:0070062
- GO:0005219
- GO:0015278
- GO:0048763
Related records
Trials (250)
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- ยง Procaine Periarticular Injections for Pain Reduction in Elderly With Osteoarthritis
- A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
- A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
- A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
- A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
- A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
- A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
- A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects
- A Possible Therapeutic Role for Adenosine During Inflammation
- A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
- A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
- A Study of Caffeine on Cardiac Arrhythmias
- A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants
- A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
- A Study of LY4515100 in Healthy Participants
- A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
- A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
Drugs (6)
- Adenosine triphosphate
- Caffeine
- Dantrolene Ryanodine receptor 1 antagonist
- Dantrolene sodium Ryanodine receptor 1 antagonist
- Procaine
- Suramin